Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.04 - $0.13 $1,564 - $5,083
-39,100 Reduced 53.86%
33,500 $2,000
Q3 2023

Nov 14, 2023

SELL
$0.12 - $0.5 $7,560 - $31,500
-63,000 Reduced 46.46%
72,600 $9,000
Q2 2023

Aug 14, 2023

BUY
$0.43 - $0.65 $30,960 - $46,800
72,000 Added 113.21%
135,600 $69,000
Q1 2023

May 15, 2023

BUY
$0.46 - $0.81 $6,624 - $11,664
14,400 Added 29.27%
63,600 $40,000
Q4 2022

Feb 14, 2023

SELL
$0.5 - $261.0 $5,750 - $3 Million
-11,500 Reduced 18.95%
49,200 $31,000
Q3 2022

Nov 14, 2022

BUY
$1.04 - $322.5 $47,320 - $14.7 Million
45,500 Added 299.34%
60,700 $104,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $458M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.